CIAS
ATRA icon

Capital Investment Advisory Services’s Atara Biotherapeutics ATRA Stock Holding History

Capital Investment Advisory Services’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4
Closed -$1K – 594
2019
Q3 		$1K Hold
4
– – ﹤0.01% 1303
2019
Q2 		$2K Hold
4
– – ﹤0.01% 1262
2019
Q1 		$4K Buy
+4
New +$3.72K ﹤0.01% 1000

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Capital Investment Advisory Services's ATRA Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Atara Biotherapeutics (ATRA) in Q4 2019, closing a stake of 4 shares — an estimated $1K sold.

Capital Investment Advisory Services first reported a position in ATRA in Q1 2019 and held it in 3 quarters. The position peaked at $4K in Q1 2019. 117 funds tracked by Wall St. Rank hold ATRA as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Atara Biotherapeutics position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 4 Atara Biotherapeutics shares in Q4 2019, an estimated $1K.
  • Capital Investment Advisory Services first reported a position in Atara Biotherapeutics in Q1 2019 and held it in 3 quarters.
  • Capital Investment Advisory Services's Atara Biotherapeutics position peaked at $4K in Q1 2019.
  • 117 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.